Research
Report on " PharmaPoint: Acute Coronary Syndrome - Global Drug
Forecast and Market Analysis to 2025 ".
Cardiovascular
diseases (CVD), including ischemic heart disease and stroke, are the
leading causes of mortality in the world. The term acute coronary
syndrome (ACS) applies to a spectrum of acute CVD states that are
precipitated by coronary artery occlusion (stenosis) that results in
ischemia (a reduction or loss of blood flow to tissue) and the
necrosis of myocardial tissue .In the most modern use of the term,
ACS strictly refers to a range of ischemic cardiovascular events that
includes unstable angina (UA), myocardial infarction (MI) and/or
death due to myocardial ischemia. In general, these ACS events can be
viewed as the culmination of coronary artery disease (CAD), the
asymptomatic build-up of atherosclerotic plaque on the walls of the
coronary arteries. The triggering of an ACS event stemming from UA or
MI initiates the acute phase treatment setting where therapeutic
interventions are utilized to reverse and prevent the physiochemical
processes that lead to coronary stenosis. Whereas, the chronic phase
treatment setting involves secondary preventative measures that are
used to avoid recurrent ACS events from occurring.
View Report At
:http://www.marketresearchreports.biz/analysis/862829
Highlights
Key Questions Answered
-
The new generation antiplatelets, Brilinta and Effient will see a
significant increase in patient shares for the treatment ACS against
the previous cornerstone, clopidogrel. However, there are
considerably high unmet needs within the indication. What are the
main unmet needs in this market? Will the drugs under development
fulfil the unmet needs of the ACS market?
-
The PCSK9 inhibitors recently launched into the CV market, and these
are predicted to have a notable impact in the ACS space once their CV
outcomes data is shown. The most notable candidate in the current
late-stage ACS pipeline is ETC-1002, which is vying to target the
needed statin intolerant ACS population. Will these newly marketed
and late-stage drugs make a significant impact on the ACS market?
Which of these drugs will have the highest peak sales at the highest
CAGR, and why?
-
We have seen a notable increase in the ACS population in terms of
diagnosed prevalent ACS cases , as well as ACS hospitalisations
(incidence and recurrent events). How will epidemiological changes
impact the growth of the future market?
Key Findings
-
The main driver of the significant expansion of the ACS market will
be the increase in use and physician confidence in the PCSK9
inhibitor class, which will hold four major players by the end of
this forecast. Novel lipid lowering therapy, ETC-1002, will also be a
major contributor, vying to steal majority of patient shares for the
statin intolerant ACS population by the end of this forecast.
-
The major global barrier for the ACS market will be the generic
erosion of the key antiplatelet therapies, Brilinta and Effient by
the end of this forecast. Both drugs will pick up significant
momentum in sales prior to patent expiry.
-
The dynamics of the ACS market will shift greatly towards solving the
atherosclerotic burden associated in ACS from the historical strategy
of developing antithrombotic therapies.
-
The key market opportunities lie in addressing unmet needs through
the development of optimal agents for secondary prevention by
controlling lipid levels and repairing the damaged myocardium post
myocardial infarction to prevent comorbidities such as heart failure.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/862829
Scope
-
Overview of ACS, including epidemiology, etiology, pathophysiology,
symptoms, diagnosis, and treatment guidelines.
-
Annualized ACS therapeutics market revenue, annual cost of therapy
and treatment usage pattern data from 2015 and forecast for ten years
to 2025.
-
Key topics covered include strategic competitor assessment, market
characterization, unmet needs, clinical trial mapping and
implications for the ACS therapeutics market.
-
Pipeline analysis: comprehensive data split across different phases,
emerging novel trends under development, and detailed analysis of
late-stage pipeline drugs.
-
Analysis of the current and future market competition in the global
ACS therapeutics market. Insightful review of the key industry
drivers, restraints and challenges. Each trend is independently
researched to provide qualitative analysis of its implications.
Reasons to buy
The
report will enable you to -
-
Develop and design your in-licensing and out-licensing strategies
through a review of pipeline products and technologies, and by
identifying the companies with the most robust pipeline. Additionally
a list of acquisition targets included in the pipeline product
company list.
-
Develop business strategies by understanding the trends shaping and
driving the global ACS therapeutics market.
-
Drive revenues by understanding the key trends, innovative products
and technologies, market segments, and companies likely to impact the
global ACS therapeutics market in future.
-
Formulate effective sales and marketing strategies by understanding
the competitive landscape and by analysing the performance of various
competitors.
-
Identify emerging players with potentially strong product portfolios
and create effective counter-strategies to gain a competitive
advantage.
-
Track drug sales in the global ACS therapeutics market from
2015-2025.
-
Organize your sales and marketing efforts by identifying the market
categories and segments that present maximum opportunities for
consolidations, investments and strategic partnerships.
Table
of Contents
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 16
1.2 List of Figures 22
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 25
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and
Pathophysiology 27
3.1.1 Etiology 27
3.1.2 Pathophysiology 31
3.2 Classification or Staging
Systems 33
3.3 Symptoms 34
3.4 Prognosis 35
3.5 Quality of Life 36
4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and
Comorbidities 38
4.3 Global Trends 41
4.3.1 ACS Diagnosed Prevalence
41
4.3.2 STEMI and NSTEMI Trends
44
4.3.3 ACS Hospitalizations 45
4.4 Forecast Methodology 47
4.4.1 Sources Used 50
4.4.2 Forecast Assumptions and
Methods 57
4.4.3 Sources Not Used 70
4.5 Epidemiological Forecast
for ACS (2015-2025) 71
4.5.1 Diagnosed Prevalent Cases
of ACS 71
4.5.2 Age-Specific Diagnosed
Prevalent Cases of ACS 73
4.5.3 Sex-Specific Diagnosed
Prevalent Cases of ACS 75
4.5.4 Diagnosed Prevalent Cases
of ACS Segmented by STEMI, NSTEMI, and UA 77
4.5.5 Age-Standardized
Diagnosed Prevalence of ACS 79
4.5.6 ACS Hospitalizations 80
4.5.7 Sex-Specific ACS
Hospitalizations 82
4.5.8 ACS Hospitalizations
Segmented by STEMI, NSTEMI, and UA 84
4.6 Discussion 86
4.6.1 Epidemiological Forecast
Insight 86
4.6.2 Limitations of the
Analysis 87
4.6.3 Strengths of the Analysis
88
5 Disease Management 90
5.1 Diagnosis and Treatment
Overview 90
5.1.1 Diagnosis 90
5.1.2 Treatment Guidelines and
Leading Prescribed Drugs 91
5.1.3 Clinical Practice 96
5.2 US 99
5.3 5EU 102
5.4 Japan 106
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment